Ronnie Wang
Overview
Explore the profile of Ronnie Wang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
67
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yun S, Palladini G, Anderson L, Cariou E, Wang R, Angeli F, et al.
Amyloid
. 2024 Sep;
31(4):291-301.
PMID: 39245873
Background: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed cause of heart failure (HF). Methods: This epidemiology study assessed the international prevalence of ATTR-CM among patients aged ≥60 years with a...
2.
Drachman B, Damy T, Hanna M, Wang R, Angeli F, Garcia-Pavia P
Eur J Heart Fail
. 2024 Jun;
26(9):2038-2046.
PMID: 38932583
Aims: Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) present with diverse left ventricular ejection fraction (LVEF). This study assessed tafamidis efficacy by baseline LVEF in the phase 3 Tafamidis in Transthyretin...
3.
Gomez R, Khadilkar V, Shembalkar J, Chu D, Ko C, Wajnrajch M, et al.
J Pediatr Endocrinol Metab
. 2024 May;
37(6):525-531.
PMID: 38717038
Objectives: Somatrogon is a long-acting recombinant human growth hormone used to treat patients with paediatric growth hormone deficiency (pGHD). This global phase 3 study compared the efficacy and safety of...
4.
Ponti L, Hsu K, Damy T, Villacorta E, Verheyen N, Keohane D, et al.
Front Cardiovasc Med
. 2023 Sep;
10:1238843.
PMID: 37711563
Background: The humanistic burden of transthyretin amyloid cardiomyopathy (ATTR-CM) is poorly defined. Methods: An international study to comprehensively characterize the burden of ATTR-CM on patients naïve to disease-modifying therapy and...
5.
Titievsky L, Schuster T, Wang R, Younus M, Palladino A, Quazi K, et al.
Orphanet J Rare Dis
. 2022 Apr;
17(1):145.
PMID: 35365177
Background: Limited real-world data from routine clinical care are available on the safety and effectiveness of treatment with taliglucerase alfa in patients with Gaucher disease (GD). Methods: Taliglucerase Alfa Surveillance...
6.
Kushner 4th J, Lamba M, Stock T, Wang R, Nemeth M, Alvey C, et al.
Eur J Pharm Sci
. 2019 Dec;
147:105200.
PMID: 31863865
Purpose: To determine if a validated Level A in-vitro in-vivo correlation (IVIVC) could be achieved with the extrudable core system (ECS) osmotic tablet platform. Tofacitinib is an oral JAK inhibitor...
7.
Cutrell A, Donnell D, Dunn D, Glidden D, Grobler A, Hanscom B, et al.
HIV Clin Trials
. 2017 Oct;
18(5-6):177-188.
PMID: 29039265
Pre-exposure prophylaxis (PrEP) has demonstrated remarkable effectiveness protecting at-risk individuals from HIV-1 infection. Despite this record of effectiveness, concerns persist about the diminished protective effect observed in women compared with...
8.
Rockstroh J, Plonski F, Bansal M, Fatkenheuer G, Small C, Asmuth D, et al.
Antivir Ther
. 2016 Dec;
22(3):263-269.
PMID: 27924779
Background: In the primary 48-week analysis of a hepatic safety trial in patients with HIV-1 coinfected with HBV and/or HCV, maraviroc-containing treatment regimens were not associated with increased hepatotoxicity. Methods:...
9.
Menon S, Riese R, Wang R, Alvey C, Shi H, Petit W, et al.
Clin Pharmacol Drug Dev
. 2016 May;
5(5):336-42.
PMID: 27138968
Tofacitinib is an oral Janus kinase inhibitor. Tofacitinib metabolism is primarily mediated by cytochrome P450 3A4. This phase 1 randomized, open-label, 2-way crossover study (NCT01137708) evaluated the effect of tofacitinib...
10.
Vourvahis M, Wang R, Mendes da Costa L, Wang C, Weatherley B, Mukwaya G, et al.
Clin Pharmacol Drug Dev
. 2016 Apr;
3(6):472-6.
PMID: 27129121
No abstract available.